lychnopholide profile

lychnopholide: isolated from Vanillosmopsis erythropappa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	49767028
CHEMBL ID	4476580
MeSH ID	M0389543

Synonym
(dimethyl-methylene-dioxo-[?]yl) (z)-2-methylbut-2-enoate
(-)-lychnopholide
2-butenoic acid, 2-methyl-, 2,3,3a,4,5,6,7,11a-octahydro-6,10-dimethyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca[b]furan-4-yl ester, [3ar-[3ar,4s(z),6r,10z,11ar]]-
77448-64-7
lychnopholide
nsc669145
2-butenoic acid, 2-methyl-, 2,3,3a,4,5,6,7,11a-octahydro-6,10-dimethyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca(b)furan-4-yl ester, (3ar-(3ar,4s(z),6r,10z,11ar))-
nsc 669145
CHEMBL4476580
[(2z,4r,8r,9s,11r)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (z)-2-methylbut-2-enoate
DTXSID401317753
AKOS040752796

Excerpt	Reference	Relevance
"Lychnopholide is a sesquiterpene lactone usually obtained from Lychnophora and Eremanthus species and has pharmacological activities that include anti-inflammatory and anti-tumor. "	( Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic application. Diniz, A; Kimura, E; Lachi-Silva, L; Lopes, JLC; Lopes, NP; Montanha, MC; Silva, DB; Sousa, JPB; Sy, SKB, 2016)	2.13

Excerpt	Reference	Relevance
" However, little is known regarding possible adverse effects of lychnopholide."	( Biodegradable Polymeric Nanocapsules Prevent Cardiotoxicity of Anti-Trypanosomal Lychnopholide. Aimond, F; Branquinho, RT; de Lana, M; Farah, C; Garcia, GM; Grabe-Guimaraes, A; Le Guennec, JY; Mosqueira, VC; Richard, S; Roy, J; Saude-Guimarães, DA, 2017)	0.92

Excerpt	Reference	Relevance
"The pharmacokinetic properties of a new molecular entity are important aspects in evaluating the viability of the compound as a pharmacological agent."	( Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. de Sousa, JP; Derendorf, H; Diniz, A; Kimura, E; Lachi-Silva, L; Lopes, JL; Lopes, NP; Silva, DB; Sy, SK; Voelkner, A, 2015)	0.65
" This rapid and sensitive method for the analysis of the sesquiterpene lactone lychnopholide in rat plasma can be applied to pharmacokinetic studies of this compound."	( Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic application. Diniz, A; Kimura, E; Lachi-Silva, L; Lopes, JLC; Lopes, NP; Montanha, MC; Silva, DB; Sousa, JPB; Sy, SKB, 2016)	0.91

Excerpt	Reference	Relevance
" The oral bioavailability was approximately 68 %."	( Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. de Sousa, JP; Derendorf, H; Diniz, A; Kimura, E; Lachi-Silva, L; Lopes, JL; Lopes, NP; Silva, DB; Sy, SK; Voelkner, A, 2015)	0.65

Excerpt	Relevance	Reference
" LYC presented 100% dissolution after 24 h, whereas only 60% of LYC was released from the nanocapsule dosage form, with no burst effect."	( HPLC-DAD and UV-spectrophotometry for the determination of lychnopholide in nanocapsule dosage form: validation and application to release kinetic study. Branquinho, RT; de Lana, M; de Souza, J; Dorim, DD; Kano, EK; Mosqueira, VC; Saúde-Guimarães, DA, 2014)	0.65
" The present lychnopholide intravenous dosage form showed great potential for further pre-clinical and clinical studies in Chagas disease and cancer therapies."	( Increased Body Exposure to New Anti-Trypanosomal Through Nanoencapsulation. de Lana, M; Marques Milagre, M; Mosqueira, VCF; Pound-Lana, G; Saúde-Guimarães, DA; Spangler Andrade, M; Tupinambá Branquinho, R; Vilela, JMC, 2017)	0.82

Assay ID	Title	Year	Journal	Article
AID1557468	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID1557481	Antiproliferative activity against human SNB19 cells	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Potential Anticancer Agents Characterized from Selected Tropical Plants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	10 (76.92)	24.3611
2020's	2 (15.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (15.38%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (84.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	2.31	1	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	3.9	3	C-nitro compound; imidazoles	antitubercular agent
calotropin calotropin: structure in first source	3.31	1	cardenolide glycoside
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	3.9	3	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
parthenolide [no description available]	3.31	1	germacranolide
justicidin a justicidins: from Justica procumbens	3.31	1	lignan
sitosterol, (3beta)-isomer Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3.	3.31	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol	anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	3.31	1	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
sesquiterpenes [no description available]	5.08	12
amentoflavone [no description available]	3.31	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
chrysosplenetin b chrysosplenetin B: constituent of the root of Berneuxia thibetica Decne. chrysosplenetin : A tetramethoxyflavone that is the 3,6,7,3'-tetramethyl ether derivative of quercetagetin.	3.31	1	dihydroxyflavone; tetramethoxyflavone	antiviral agent; plant metabolite
euxanthone euxanthone : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1 and 7 and an oxo group at position 9. It has been isolated from Cratoxylum cochinchinense.	3.31	1	phenols; xanthones	metabolite; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	3.31	1	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
furanoheliangolide furanoheliangolide: structure in first source	4.04	3
artonin e artonin E: structure given in first source; isolated from the bark of Artocarpus communis Forst.	3.31	1
gambogic acid gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer	3.31	1	pyranoxanthones	metabolite
morelloflavone morelloflavone: also inhibits cruzain; RN given for (2S-trans)-isomer; structure in first source. (+)-morelloflavone : A biflavonoid found in Rheedia edulis and Garcinia livingstonei.	3.31	1	biflavonoid; hydroxyflavanone; hydroxyflavone	plant metabolite
15-deoxygoyazensolide 15-deoxygoyazensolide: an NSAID with schistossomicidal and trypanosomicidal activities; structure in first source	3.31	1
eremantholide c eremantholide C: structure in first source	2.55	2	furofuran

Condition	Relationship Strength	Studies
Benign Neoplasms, Brain [description not available]	2.25	1
Astrocytoma, Grade IV [description not available]	2.25	1
Glial Cell Tumors [description not available]	2.25	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.25	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.25	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.25	1
Innate Inflammatory Response [description not available]	2.31	1
Gouty Arthritis [description not available]	2.31	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.31	1
Arthritis, Gouty Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular. Acute and chronic gouty arthritis are associated with accumulation of MONOSODIUM URATE in and around affected joints.	2.31	1
Cardiac Toxicity [description not available]	2.15	1
American Trypanosomiasis [description not available]	3.95	4
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	8.95	4
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	7.15	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.52	2
Chronic Illness [description not available]	2.13	1
Acute Disease Disease having a short and relatively severe course.	2.13	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.13	1
Anasarca [description not available]	2.08	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.08	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.1	1
Abnormalities, Autosome [description not available]	2	1

lychnopholide

Description

Cross-References

Synonyms (12)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Bioassays (2)

Research

Studies (13)

Market Indicators

Research Demand Index: 13.14

Study Types

lychnopholide

Description

Cross-References

Synonyms (12)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Bioassays (2)

Research

Studies (13)

Market Indicators

Research Demand Index: 13.14

Study Types

Related Drugs (19)

Related Conditions (22)